Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioDlink International Company Limited (1875.HK)
HKD3.71
+0.31 (+9.12%)
CN HKSE Healthcare Biotechnology
Address
No. 120 Changyang Street 215024
Suzhou, CN
Suzhou, CN
CEO
Shan Fu
Website
totbiopharm.com.cn
IPO
2019-11-08
ISIN HK0000545266
Description
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD3.71
+0.31 (+9.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
-0.13
Float Shares
308.56M
Free Float %
42.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.73% | -7.38% | -11.91% | +0.98% | +132.58% | +65.60% | +114.51% | +62.35% | -8.20% | -33.87% | -33.87% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.71
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.42
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-31.9% Q4'25: -42.9% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-392.3% Q4'25: -348.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-7.4% Q4'25: -15.7% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-10.8% Q4'25: -34.6% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-11.8% ★ Q4'25: -52.5% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-59.61× Q4'25: -3.58× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
45.31M
est: 64.88M (-30.2%)
|
22.49M
est: 63.09M (-64.4%)
|
76.33M
est: 63.70M (+19.8%)
|
442.18M
est: 418.85M (+5.6%)
|
780.63M
est: 600.53M (+30.0%)
|
1.10B
est: 1.09B (+0.4%)
|
747.65M
est: 1.38B (-45.7%)
|
1.68B
1.68B – 1.68B
+21.6% YoY
|
| EBITDA |
-240.07M
est: -24.93M (-862.9%)
|
-254.71M
est: -336.93M (+24.4%)
|
-224.51M
est: -1.42B (+84.1%)
|
-5.41M
est: -1.95B (+99.7%)
|
10.45M
est: -5.63B (+100.2%)
|
84.96M
est: -19.43B (+100.4%)
|
-6.44M
est: -256.30M (+97.5%)
|
-311.77M
-311.77M – -311.77M
-21.6% YoY
|
| EBIT |
-297.01M
est: -27.22M (-991.0%)
|
-286.79M
est: -301.14M (+4.8%)
|
-258.75M
est: -1.26B (+79.5%)
|
-43.44M
est: -1.75B (+97.5%)
|
-32.58M
est: -5.04B (+99.4%)
|
46.16M
est: -17.37B (+100.3%)
|
-80.49M
est: -332.22M (+75.8%)
|
-404.13M
-404.13M – -404.13M
-21.6% YoY
|
| Net Income |
-299.30M
est: -914.57M (+67.3%)
|
-288.50M
est: -334.31M (+13.7%)
|
-261.22M
est: -1.40B (+81.4%)
|
-49.92M
est: -1.94B (+97.4%)
|
-37.76M
est: -5.59B (+99.3%)
|
34.76M
est: -19.28B (+100.2%)
|
-100.37M
est: 86.99M (-215.4%)
|
135.49M
135.49M – 135.49M
+55.8% YoY
|
| SGA |
126.64M
est: 79.88M (+58.5%)
|
72.81M
est: 77.68M (-6.3%)
|
79.19M
est: 78.43M (+1.0%)
|
266.54M
est: 515.72M (-48.3%)
|
509.33M
est: 739.42M (-31.1%)
|
688.09M
est: 756.31M (-9.0%)
|
401.58M
est: 952.45M (-57.8%)
|
1.16B
1.16B – 1.16B
+21.6% YoY
|
| EPS |
-0.58
est: -1.26 (+54.0%)
|
-0.51
est: -0.42 (-21.7%)
|
-0.46
est: -0.39 (-17.8%)
|
-0.08
est: -0.02 (-292.8%)
|
-0.05
est: -0.08 (+38.5%)
|
0.05
est: 0.09 (-46.8%)
|
-0.14
est: 0.12 (-216.7%)
|
0.19
0.19 – 0.19
+55.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.75B
OE per share TTM
2.41
Owner's Yield
58.22%
Maintenance CapEx ratio
4,041.50%
Maint CapEx / Avg PPE
115.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-131.7K
Shares Outstanding
725.20M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ben Xiao | Group Vice President of Finance & Investor Relations | — | female |
| Jian Bo Zhang | Chief Operating Officer | — | — |
| Jincai Li | Executive Director | — | — |
| Li Yin | Chief Technology Officer | — | female |
| Shan Fu | Executive Chairperson of the Board | — | male |
| Wing Yat Lui | Joint Company Secretary | — | male |
| Yifan Chen | Joint Company Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1875.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
